Extended Data Fig. 4: Cellular LNP delivery in the spleen and placenta for industry and clinical standard LNPs in healthy and inflammation-induced pre-eclamptic mice.
From: Placenta-tropic VEGF mRNA lipid nanoparticles ameliorate murine pre-eclampsia
To evaluate differences in biodistribution between healthy and pre-eclamptic pregnant mice,inflammation-induced pre-eclampsia was established via i.p. administration of 1 µg kg−1 lipopolysaccharide (LPS). DiD-labelled LNPs 97 and 98 were administered at an mRNA dose of 1 mg kg−1. Twelve hours later, cellular LNP delivery was evaluated in the (a–f) spleen and (g–l) placenta via flow cytometry. The percentage of DiD+ cells is reported as the mean ± s.e.m. (PBS, LNP 97, LNP 98, LPS + LNP 98: n = 4 biological replicates; LPS + LNP 97: n = 3 biological replicates). Either ordinary (a–f) or nested (g–l) two-sided, one-way ANOVAs with post hoc Student’s t tests using the Holm-Šídák correction for multiple comparisons were used to compare the percentage of DiD+ cells across treatment groups. CK7: cytokeratin 7.
